Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, announced the initial close of an oversubscribed Series E financing.
Read also – [Funding News] Micropep Raises $29 Million Series B Funding
On the occurrence of the initial closing and upon the request of the company, one or more additional closings of this Series E financing, such that the aggregate amount of this Series E financing will be $150 million.
Read also – [Funding News] GeoWealth Secures $18 Million Growth Funding Led by BlackRock
The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also included participation from new investors, including Catalio Capital Management, LP, HealthCor Family Office, Montreux Growth Partners, and INTAI Technology Corp.
“We are grateful for the continued support of our existing investors and welcome our new investors who share our vision for leadership in stroke and vascular thrombectomy,” said Fred Khosravi, Chairman and CEO of Imperative Care. “This latest financing fuels our hypergrowth strategy as we work to make better care accessible to more patients. We will continue to invest in novel technologies and clinical evidence to measure the impact of these technologies on patient outcomes.”
“As investors in Imperative Care since the company’s Series C financing in December 2019, we have been impressed with the dramatic progress the company has made on many fronts, including treating more than 45,000 patients with life-saving technologies,” said Ally Bridge founder and CEO Frank Yu, who has also served as a Director on the Imperative Care Board since 2019. “We are excited to support the next stage of Imperative Care’s success, as the company strengthens its position for treating ischemic stroke and prepares to make a major contribution to the treatment of peripheral vascular disease.”
About Imperative Care, Inc.
Founded in 2015, Imperative Care is a Silicon Valley-based medical technology company researching and developing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company has four businesses focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey.
